secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000950170-24-119014
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q3 revenue $45M, net loss improves 34.6% YoY; reaffirms FY2024 outlook
--------------------------------------------------------------------------------

- Q3 2024 revenue $45.0M (-5% YoY pro forma); net loss $26.9M improved from $41.2M loss YoY.
- Adjusted EBITDA loss $14.2M vs $28.2M loss YoY, a 49.6% improvement; merger synergies $80M on track for 2025.
- Consumables revenue up 13% to $14.0M; Instruments down 42% to $5.6M due to capital constraints, especially China.
- FY2024 revenue guidance reaffirmed at $170M-$175M; path to adjusted EBITDA break-even in 2026.
- Cash and short-term investments $367.6M; gross margin 51.7% (42.5% YoY), non-GAAP gross margin 56.9%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095017024119014/0000950170-24-119014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095017024119014/lab-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-119014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer